


**Figure S7 (Related to Figure 6). Changes in the status of recipient-derived smooth muscle cells.**

(A) Immunostaining for Ki67, PDGFR- $\alpha$  and  $\alpha$ -SMA in 1, 2, 3, and 4 weeks after transplantation. n = 6 per group. Data are presented as mean  $\pm$  SEM. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001. (B) UMAP plots showing 4 groups and proportions (chemotaxis/proliferation/secretion/contraction) in the normal thoracic aorta and 4-week aortic graft. (C) Heatmap showing average scaled expression levels of top DEGs in SMCs clusters. (D) Pseudotime trajectories showing states of the SMC clusters. (E) Heatmap showing the functions and cell fate in SMCs cluster1-3. (F) Gene set enrichment analyses showing the top 10 enriched gene ontology biological processes (GOBP) in SMC clusters.



**Figure S8 (Related to Figure 7). Proliferation and migration of smooth muscle in vitro are regulated by CCL11 and CCR3.**

(A) CCK8 proliferation assay of SMCs cultured with PBS, CCL11-plasmid and CCR3-siRNA for 12h (n = 6 per group). (B) Representative migration images of SMCs cultured with PBS, CCL11-plasmid and CCR3-siRNA for 12h (n = 6 per group). Right panel: quantification analysis of migration rates of SMCs among these three groups. (C) Representative scratch-healing images of SMCs cultured with PBS, CCL11-plasmid and CCR3-siRNA for 12h (n = 6 per group). Right panel: quantification analysis of scratch-healing rates of SMCs among these three groups. (D) qPCR analyses showing gene expression of these markers (SM22/ $\alpha$ -SMA/PDGFR- $\alpha$  /Vimentin/Postn) in normal aorta and allograft 4 weeks (n = 6 per group). (E) qPCR analyses showing gene expression of these markers (SM22/ $\alpha$ -SMA/Collagenase1/MMP2/MMP9) in normal SMC group and recombinant CCL11-treating group (n = 6 per group). Cells were treated with recombinant CCL11 10ng/ul for 12h. (F) qPCR analyses showing gene expression of these markers (SM22/MMP2/MMP9) in recombinant CCL11-treating SMC group and recombinant CCL11 combined CCR3-siRNA-treating SMC group (n = 6 per group). SMCs were treated with recombinant CCL11 10ng/ul for 12h or CCR3-siRNA 10nmol for 24h. (G) Representative western blot images of these markers(CCL11/ $\alpha$ -SMA/ Osteopontin) in SMCs treated with PBS, CCL11-plasmid and CCR3-siRNA for 12h (n = 6 per group). Right panel: quantification analysis of these markers. Data were presented as the mean  $\pm$  SEM and analyzed by using an unpaired two-tailed Student's t-test. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001.